

2020
ANNUAL REPORT



“The Pediatric Cancer Research Foundation Identifies and Funds Leading Edge Researchers that Demonstrate the Best Hope for a Cure to Childhood Cancer.”

ELIMINATING CHILDHOOD CANCER THROUGH LEADING EDGE RESEARCH.



Cancer is the **LEADING CAUSE OF DEATH** by disease in children under 19 years of age in the US



Every year, an estimated 300,000+ new cases of cancer affect children worldwide – that's over **800 NEW KIDS AFFECTED EVERY DAY**



ONE IN 285 in the U.S. will be diagnosed with cancer by the time they are 20 years old



ONE QUARTER of childhood cancer survivors face a late effect from treatment that is classified as severe or life-threatening



Childhood cancer survivors are **TWICE AS LIKELY** to suffer chronic health conditions

FILLING A GAPING VOID

“Childhood Cancer Research Receives Just 4% of the Annual Research Budget from the National Cancer Institute”



An estimated **50%** of childhood cancer research is **FUNDED BY PRIVATE PHILANTHROPY**

Most **EARLY-STAGE RESEARCH** is funded by **PHILANTHROPIC SUPPORT**; generally, NCI funding commences upon scientific validation

- Investment by private industry tends to be focused on later stage clinical research



DOLLARS EXPENDED THRU 2020 SINCE INCEPTION

Cancer Research Programs
\$38,595,589 / 75.2%

Fundraising and G&A
\$9,946,549 / 19.4%

Reserves
\$ 2,778,200 / 5.4%

Total Dollars Raised
\$51,320,338 / 100%

STATEMENT OF FINANCIAL POSITION

OPERATING REVENUE & OTHER SUPPORT

	2020	2019
General Public Support	\$2,426,508	\$1,703,148
Special Events and Programs	\$706,747	\$1,258,757
CARES Act Income	\$100,500	
TOTAL REVENUE & SUPPORT	\$3,233,755	\$2,961,905
EXPENSES		
Program Services -		
Pediatric Cancer Research	\$2,126,954	\$2,424,143
Supporting Services		
Management and General	\$171,832	\$214,946
Fundraising	\$413,204	\$416,312
TOTAL EXPENSES	\$2,711,990	\$3,055,401
INCREASE (DECREASE) IN NET ASSETS	\$521,765	(\$93,496)
UNRESTRICTED NET ASSETS AT BEGINNING OF YEAR	\$2,256,435	\$2,349,931
UNRESTRICTED NET ASSETS AT END OF YEAR	\$2,778,200	\$2,256,435



PLANNING FOR THE FUTURE


Make a lasting mark and leave a family legacy by naming the Pediatric Cancer Research Foundation in your estate. Besides the philanthropic satisfaction of making a gift to PCRf, there are significant tax benefits that may provide you with the opportunity to give more than you thought possible. For example, Patrick and Kaye Collins carefully planned their estate, ultimately making a considerable impact on PCRf in 2020. Initially getting involved through the holiday card program and then the National Corvette Restorers Society, the Collins' saw the need for funding. So when they drafted their will decades ago, they decided to leave their entire estate to PCRf.

The impact of this gift allowed us to continue much-needed research in a year that offered up so much uncertainty. We invite you to join our Hope Society by including us in your estate plan, trust, gift annuity, insurance policy, or retirement plan.

Please, help us plant the seeds for tomorrow's cures to childhood cancer.

Your estate gift can leave a lasting legacy at the Pediatric Cancer Research Foundation.

To learn more about including PCRf in your estate planning, please get in touch with our office.



CHARITY RATING

"The Pediatric Cancer Research Foundation continues to receive the Platinum rating from GuideStar as one of the highest philanthropy scores awarded. Donors can have confidence in PCRf's ability to fund the best researchers in the world, with the utmost attention to financial efficacy and transparency."



Researchers We Fund 2020

Mitchell Cairo
New York Medical College
PCRF Laboratory at
New York Medical College

Anat Erdreich-Epstein
Children's Hospital, Los Angeles
Medulloblastoma

Kathleen Sakamoto
Stanford university
Leukemia/ Lymphoma

Alex Huang
Case Western Reserve University
Osteosarcoma

Surojit Sarker
Seattle Children's Hospital
Immunotherapy/ Solid Tumors

Sarah Injac
Baylor College of Medicine
Medulloblastoma

Shulin Li
MD Anderson Cancer Center
Solid Tumors

Ting Tao
Dana-Farber Cancer Institute
Neuroblastoma

Lingling Chen
Johns Hopkins University-
School of Medicine
Rhabdomyosarcoma


Stewart Goldman
Ann & Robert H. Lurie Children's
Hospital of Chicago
Gliomas/ DIPG

Agnieszka Czechowicz
Stanford University
Acute Myeloid Leukemia

Markus Muschen
City of Hope
Acute Lymphoblastic Leukemia

Brain Crompton
Dana Farber Cancer Institute
Ewing Sarcoma

Elliot Stieglitz
University of California, San Francisco
Juvenile Myelomonocytic Leukemia





Highlights in Research 2020

With your support grants funded by your donations supported these cutting edge researchers that gleaned the following advancements. You can be proud of your support at PCRF. This is an elite team that continues to do leading research through your donations. Here are some of the highlights from just a few of the team listed.

- Dr. Mitchell Cairo has been pivotal in curing advanced mature B-NHL in children and adolescents and in reducing their toxic exposure and length of therapy. The result: they can lead healthier lives in the future and spend less time in the hospital while receiving therapy. In 1982 standard treatment was 2.5 years of chemotherapy and radiotherapy. Only 30 % of patients with advanced disease were alive in two years. Today chemotherapy has been reduced to 90 days with no radiation, with 100% overall 2-year survival.
- Alex Huang, M.D., Ph.D. has demonstrated the potential for immunotherapy to treat osteosarcoma, offering one of the only new treatments in almost 20 years. The breakthroughs – in areas previously thought impossible to advance – mean new treatments for Adolescent & Young Adult (AYA) patients who previously had no options.
- Elliott Stieglitz, M.D., is working on diagnostic tests that predict which patients are likely to respond positively to the intensive treatment to JMML. This risk stratification is significant because it allows for treatment decisions to be optimized, giving patients a higher likelihood of success in a disease with 50% survival rate reaching their full potential. Thank you for being part of helping to power cures and realize future.
- Kathleen Sakamoto, M.D., Ph.D., has advanced treatments for children with acute myeloid leukemia (AML) since 2008. Armed with the insight that a protein called CREB is overproduced in AML patients and results in a worse prognosis, research has focused on developing newer and better drugs to block CREB – causing AML cells to die. One drug is now in Phase 1 Trials; other work is underway to model the structure of CREB and its binding partner, CBP, in hopes of identifying new molecules that prevent them from binding to each other.

We continue to make strides year after year to give children a chance at reaching their full potential. Thank you for being part of helping to power cures and realize future.

Leadership

Officers:

Steve Giusto
Chairman

John Weiner
Vice President

Thomas Brennan
Treasurer

Keith Koeller
Secretary

Troy Varenchik
Director of
Scientific Affairs

Cameron Munson
Director of
Marketing

Board of Directors:

Elizabeth McNulty
Past President

Susie Buchan
Member

John Coon
Member

Tim Cromwell
Member

Cherie Daly
Member

Scott Ecker
Member

David Goldwasser
Member

Daniel Mitchell
Member

Janet Mitchell
Member

Brad Neglia
Member

Ed Rosenblum
Member

Cornel Sneekes
Member

John Valley
Member



*IT'S MORE
THAN A JOB,
IT'S A
MISSION.*



Since 1982

40 YEARS
OF
FUNDING

PCRF

218

218 Annual Grants

70

70 Principal Investigators

37

37 Leading Institutions

420K

420,000 Childhood
Cancer Survivors

51

Raised Over \$51 million
for Innovative Research

POWERING CURES, REALIZING FUTURES



We Are Cure Seekers, Relentless in Our Quest
to Eliminate Childhood Cancer.

Please Join Us! pcrf-kids.org

Follow Us:

